RxDoctor Payments Data

Kimberly Walker, APRN

Psychiatric/Mental Health · Orangeburg, SCNPI 1861197337

Payments from drug & device makers

$1,884in general payments, 2019–2025

Across 55 payments — averaging $34.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$487
  • Johnson & Johnson$440
  • Neurocrine Biosciences, Inc.$355
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$275
  • E.r. Squibb & Sons, L.L.C.$117
  • Alpha Cognition USA, Inc.$89
  • plus $120 from 3 others

What the payments were for

  • Food & beverage$1,78495%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,884 in reported general payments places this provider in the 70th percentile of 354 psychiatric/mental health providers in South Carolina.

See all psychiatric/mental health providers in South Carolina

Medicare billing

Part B allowed, 2024
$42,345
Medicare patients
95
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$90,715
Abilify MaintenaAripiprazole11$31,764
RexultiBrexpiprazole20$18,497
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$7,835
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$2,205
Haloperidol Decanoate29$1,366
Ziprasidone Hcl17$975
Trazodone Hcl83$813
Aripiprazole35$783
Olanzapine30$715
Buprenorphine Hcl14$688
Haloperidol13$644
Divalproex Sodium12$552
Benztropine Mesylate27$528
Quetiapine Fumarate48$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$355$90,71512 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$487$50,26131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 354 psychiatric/mental health providers in South Carolina.

Other psychiatric/mental health in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →